Navigation Links
ULURU Inc. Reports First Quarter 2008 Financial Results
Date:5/12/2008

ADDISON, Texas, May 12 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today reported financial results for the first quarter ended March 31, 2008.

For the quarter ended March 31, 2008, the net loss attributable to common stockholders was $1,815,000, or $0.03 per share, compared to a net loss of $847,000, or $0.01 per share, for the corresponding period in 2007. The first quarter 2008 net loss was impacted by non-cash expenses of $497,000, which included stock option expense, amortization, and depreciation of $208,000, $269,000 and $20,000, respectively, whereas the first quarter 2007 net loss included non-cash expenses of $385,000, which included stock option expense, amortization, and depreciation of $103,000, $265,000 and $17,000, respectively.

Income Statement

Revenues for the first quarter of 2008 were $256,000, compared with $384,000 for the same period last year. The decrease of $127,000 in revenues is comprised of a decrease in licensing of $124,000 and a decrease in sponsored research of $190,000, as both of the prior year revenue components were non-recurring. These two decreases were partially offset by an increase of $20,000 in royalty income associated with our Zindaclin(R) product and $167,000 in Aphthasol(R) product sales to our domestic distributor.

Total costs and expenses, including amortization and depreciation, increased by $753,000 in the first quarter of 2008 to $2,196,000, compared with the corresponding period in 2007 where total costs and expenses, including amortization and depreciation, were $1,443,000. The overall expense increase is primarily attributable to increases in Research and Development of $310,000, increases in General and Administrative of $298,000, and Cost of Goods Sold
'/>"/>

SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
2. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
4. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. Reports Third Quarter 2007 Results
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
8. ULURU Inc. Announces Odd-Lot Buy Back Offer
9. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
10. Novadaq Reports Financial Results for the First Quarter of 2008
11. Isis Reports Financial Results and Highlights for First Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 3Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 4Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 5Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 6